To develop accurate and representative reimbursement of costs, the National Tariff needs to take account of costs disproportionately borne by activity in a small number of providers. The National Tariff separates payment for particular high cost drugs, chemotherapy and high cost devices to achieve this.
In order to keep reimbursement current, we welcome nominations for new drugs, and devices that should be separately reimbursed through local negotiation, rather than through National Tariff prices.
Similarly, we want to ensure that the chemotherapy regimens published list, in order to necessitate coding, reporting and costing of chemotherapy regimens in the NHS in England, remains current.
We are now inviting nominations for additions to, and removals from, the high cost drugs and devices lists for the next national tariff, due to come into effect in April 2019. We have created a survey to be used to submit nominations, which is available at www.engage.england.nhs.uk/survey/4ea6899d/ . The closing date for nominations is 17 November 2017.